Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights promising developments, such as the potential $25 billion market for ABS-201, strong consumer interest, and strategic focus on I&I over oncology. The company's confidence in achieving receptor occupancy and the efficient use of agentic AI for cost reduction further strengthen the outlook. Despite some withheld details, the overall sentiment is positive, with expectations of significant growth and market impact.
Key Financial Performance
Revenue $200,000 for the first quarter of 2026, with no year-over-year change mentioned.
Research and Development Expenses $19.3 million for the three months ending March 31, 2026, compared to $16.4 million for the prior year period, representing an increase primarily driven by advancement of Absci's internal programs, including direct costs associated with external preclinical and clinical development of ABS-201.
Selling, General and Administrative Expenses $9.1 million for the three months ending March 31, 2026, compared to $9.5 million for the prior year period, representing a decrease primarily due to a reduction in personnel-related costs.
Cash, Cash Equivalents, and Marketable Securities $125.7 million as of March 31, 2026, compared to $144.3 million as of December 31, 2025, reflecting a decrease due to operational expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ABS-201 for androgenic alopecia: Phase I/IIa HEADLINE trial is progressing well. Preliminary safety, tolerability, and PK data to be shared next month. Interim 13-week hair regrowth data expected in the second half of 2026, with full 26-week proof-of-concept data in early 2027. ABS-201 aims to create a new category of hair regrowth therapy with durable results from a few injections.
ABS-201 for endometriosis: Phase II clinical trial initiation planned for Q4 2026. ABS-201 has potential to address pain and underlying disease, with peak sales estimated to exceed $4 billion.
ABS-202 for I&I indication: New anti-prolactin receptor antibody announced, expanding the prolactin pipeline.
Market opportunity for ABS-201 in AGA: Potential total available market exceeding $25 billion annually in the U.S. ABS-201 could expand the AGA market as a premium category of durable regenerative hair growth therapy.
Market opportunity for ABS-201 in endometriosis: Endometriosis affects up to 10% of women worldwide, with an estimated 9 million in the U.S. ABS-201 could define a new therapy category with significant commercial potential.
Agentic AI workflows: Implementation across research, SG&A, and other functions is creating efficiency and capability gains, leading to cost savings and productivity improvements.
Financials: Revenue for Q1 2026 was $200,000. R&D expenses increased to $19.3 million due to ABS-201 development. Cash reserves of $125.7 million are projected to fund operations into the first half of 2028.
Focus on prolactin biology: Deepening pipeline with ABS-202 and deprioritizing oncology programs (ABS-301 and ABS-501) to focus on areas with higher ROI.
Partnership opportunities: Exploring early-stage asset transactions and platform collaborations with large pharma to generate non-dilutive cash inflows.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Development Risks: The development and clinical progress of ABS-201, including its Phase I/IIa HEADLINE trial and potential advancement to Phase III, are subject to regulatory approvals and timelines. Any delays or failures in meeting regulatory requirements could adversely impact the company's strategic objectives.
Market and Competitive Risks: The potential market opportunity for ABS-201 is based on assumptions about regulatory approval, competitive landscape, and product efficacy. Changes in these factors could materially affect the addressable market and commercial success of ABS-201.
Strategic Focus and Resource Allocation Risks: The decision to deprioritize oncology programs (ABS-301 and ABS-501) and focus on ABS-201 and ABS-202 could limit diversification and expose the company to higher risks if these prioritized programs fail to meet expectations.
Financial Risks: The company reported a decrease in cash reserves from $144.3 million to $125.7 million within three months. While current projections suggest sufficient funding until 2028, any unforeseen expenses or delays in achieving milestones could strain financial resources.
Operational Risks: The implementation of agentic AI workflows is expected to create efficiency gains, but any challenges in execution or integration could disrupt operations and delay progress.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ABS-201 Development Timeline: The Phase I/IIa HEADLINE trial for ABS-201 is progressing as planned. Preliminary safety, tolerability, and PK data will be shared next month. Interim 13-week proof-of-concept data will be disclosed in the second half of 2026, with full 26-week proof-of-concept data expected in early 2027. A Phase II clinical trial for endometriosis is anticipated to begin in Q4 2026, with a potential proof-of-concept readout in the second half of 2027.
ABS-201 Market Potential: ABS-201 is positioned as a novel therapy for androgenic alopecia (AGA) and endometriosis. Market research indicates a potential total available market exceeding $25 billion annually in the U.S. for AGA, with peak sales for endometriosis estimated at over $4 billion. ABS-201 aims to create a new category of durable regenerative therapies.
ABS-202 Pipeline Expansion: A new anti-prolactin receptor antibody, ABS-202, has been announced for an undisclosed indication in inflammation and immunology (I&I). This program leverages Absci's expertise in prolactin biology and AI platform.
Strategic Focus and ROI: The company is prioritizing ABS-201 development for AGA and endometriosis due to high ROI potential. Oncology programs ABS-301 and ABS-501 are being deprioritized to focus resources on programs with greater ROI potential.
Financial Outlook: Cash, cash equivalents, and marketable securities are projected to fund operations into the first half of 2028. The company is exploring non-dilutive cash inflows through early-stage asset transactions and platform collaborations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the distinctions between ABS-202 and ABS-201, and why does ABS-202 make sense for some indications versus others?
A:ABS-202 is being developed with a differentiated profile to target indications outside of AGA and endometriosis, where pricing differences may exist. It focuses on prolactin biology, which is linked to autoimmune diseases and is expressed in various parts of the body. The company is also exploring bispecifics that could synergize with this mechanism.
Q:What is the expected efficacy and market potential of ABS-201?
A:The company believes that ABS-201, with comparable efficacy to oral minoxidil and infrequent dosing, could be a 'home run' product. Consumer and dermatologist surveys suggest it could establish a new therapy category with a potential $25 billion TAM. The product could attract patients dissatisfied with current treatments and those seeking first-line therapy.
Q:What are the differences in pharmacokinetics and binding between ABS-201 and ABS-202?
A:The company is not disclosing the specific profile differences between ABS-201 and ABS-202 at this time, other than stating that ABS-202 is planned for a different indication.
Q:What should be expected from the 13-week and 26-week readouts for ABS-201?
A:The 13-week readout is directional, aiming to show hair growth, while the 26-week readout is expected to demonstrate efficacy comparable to oral minoxidil in terms of hairs per square centimeter.
Q:Has the perspective on achieving 90% receptor occupancy with the prolactin mechanism changed?
A:The company remains confident that 90% receptor occupancy is achievable with the dosing schedule envisioned, based on preliminary data and conservative scaling in the study design.
Q:Is there expected variability in therapeutic response among patients enrolled in the ABS-201 trial?
A:The company does not expect significant variability in therapeutic response due to biomarker profiles or age. The study has balanced enrollment across various stages of the Norwood classification, and no inter-subject variability has been observed in preclinical experiments.
Q:When will more details about the mechanism and properties of ABS-202 be disclosed?
A:The company is not planning to disclose additional details about ABS-202 until closer to its clinical development, citing competitive reasons.
Q:Did the consumer survey test for patient preference for combination therapy with ABS-201?
A:The survey did not specifically test for combination therapy preferences but showed high interest in ABS-201 among patients already using standard care. Interviews indicated that patients might use ABS-201 alongside existing treatments.
Q:What measures are being taken to mitigate placebo response in the endometriosis trial?
A:The company is implementing operational measures such as careful site and investigator selection, placebo training, and surveillance of blinded data. These measures are designed to mitigate placebo response, which is not explicitly detailed in the protocol but is critical for trial execution.
Q:Will ABS-202 be developed internally or partnered out?
A:The company is open to both internal development and partnering for ABS-202, depending on the market opportunity and pricing considerations.
Q:What is the benchmark for success in the ABS-201 AGA MAD portion, and what is expected at the 13-week mark?
A:The benchmark for success at 26 weeks is efficacy comparable to oral minoxidil. At 13 weeks, the company aims to see directional hair growth but has not set an official guide for this interim readout.
Q:What are the key parameters driving the dosing regimen for ABS-201?
A:Preliminary PK data from SAD cohorts suggest the potential for dosing every 8 weeks subcutaneously. More refined data will be available after MAD cohort analysis.
Q:Why is the company deprioritizing oncology products?
A:The company is focusing on assets that align with its go-to-market strategy for ABS-201, particularly in I&I, as oncology does not support this strategy. Resources are being redirected to support ABS-201 and related assets.
Q:Why has the cadence of partnerships slowed, and what is the company's strategy for partnerships?
A:The company is focusing on partnerships that align strategically with its portfolio and go-to-market strategy for ABS-201. It is prioritizing asset-based partnerships over platform-based deals to generate better economic terms and nondilutive cash flow.
Q:How is the adoption of agentic AI impacting the company's operations?
A:The company is implementing agentic AI across R&D and SG&A, leading to efficiency gains and expected cost reductions in the near term.
Q:What is the potential market size and approach for the hair repigmentation opportunity?
A:Hair repigmentation is seen as a market opportunity comparable to or larger than AGA. It is currently an exploratory endpoint, and further development will depend on the 13- and 26-week readouts.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the profile differences between ABS-201 and ABS-202, the mechanism of ABS-202, and the expected 13-week readout for ABS-201. They also did not disclose specifics about the potential partnerships for ABS-202 or the exact operational measures for mitigating placebo response in the endometriosis trial.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ABS AGA
ABS potential
AGA endometriosis
HEADLINE trial
PK
POC readout
Phase II
Sean
asset
biology
category
development ABS
dosing interval
hair regrowth
hair week
mechanism
minoxidil
opportunity AGA
patient
plan
platform
priority
product profile
projection
proof concept
receptor
research
return investment
trial ABS
week hair
workflow
ABSI Transcript
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral6-10
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral6-5
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call highlights promising developments, such as the potential $25 billion market for ABS-201, strong consumer interest, and strategic focus on I&I over oncology. The company's confidence in achieving receptor occupancy and the efficient use of agentic AI for cost reduction further strengthen the outlook. Despite some withheld details, the overall sentiment is positive, with expectations of significant growth and market impact.
Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call presents a mixed outlook. The company is actively pursuing partnerships and has a promising pipeline, which is positive. However, there are uncertainties, such as lack of FDA engagement on ABS-201's Phase III design and undisclosed pricing strategies, which create concerns. The market opportunity is significant, but the absence of clear guidance tempers optimism.
ABSI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
